drugset
Drugs / Trimethoprim/Sulfamethoxazole
last change Sep 2021 re-read 9 days ago

Trimethoprim/Sulfamethoxazole

Developed for
infectious disease
Investigated by
Radboud University Medical Center · ZonMw: The Netherlands Organisation for Health Research and Development

Trials 1

today NCT03228108 · Ph 4
201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT03228108 Apr 2018 → Sep 2021 infectious disease, prostate cancer Radboud University Medical Center Completed Missed primary

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Trimethoprim/Sulfamethoxazole ClinicalTrials.gov intervention name — accepted as the source's own label NCT03228108 ↗
Route Oral “trimethoprim/sulfamethoxazole (SXT) 960 mg orally 2 hours before and 12 hours after prostate biopsy” NCT03228108 ↗